HR 10858 — 119th Congress

CARE for Blood Cancer Act of 2026

Introduced Oct 22, 2026 Open for voting
Note: Bill summaries and components on this page are AI-generated and may contain errors. Always consult the original bill text and official sources before relying on this information.
← Open legislation
Click Vote to enable simultaneous voting.

Funding / Appropriations Top 3

Grants for Blood Cancer Awareness and Education

Authorizes grants to state, local, tribal, and nongovernmental health entities to research best practices for blood cancer awareness and education, with priority given to communities with high blood cancer rates or significant mortality.

  • Population Scope Medium Grants flow directly to a bounded set of state, local, tribal, and nongovernmental health entities, but the downstream awareness campaigns they fund could reach a broad general public audience indirectly.
  • Budgetary Magnitude Medium No specific dollar amount is authorized or appropriated; the program creates competitive grant authority whose scale is entirely subject to future appropriations.
  • Legal / Regulatory Depth Medium Creates a new statutory grant entitlement class with defined eligibility criteria and a mandatory priority-setting rule — a new procedural-plus-substantive duty on the Department of Health and Human Services (HHS) Secretary, but not a broad mandate restructuring existing law.
  • Degree of Discretion Granted High The Secretary of Health and Human Services must award grants ('shall') but retains wide latitude to define 'qualified nongovernmental entity,' set award amounts, and determine what constitutes a high-risk community — broad delegated judgment on all substantive criteria.
  • Implementation & Enforcement Burden Low No enforcement mechanisms, penalties, or compliance obligations are created; the only administrative load is grant award and oversight within an existing HHS infrastructure.
  • Temporal Commitment High The grant authority operates indefinitely with no sunset, expiry, or mandatory reauthorization, persisting until Congress affirmatively acts to end it.
No signal yet

Core Policy Mechanism Top 3

National Blood Cancer Program Establishment

Creates a new federal program to coordinate blood cancer awareness, health professional education, and patient support across federal agencies including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Health Resources and Services Administration (HRSA).

  • Population Scope Medium The program targets blood cancer patients, caregivers, and health professionals — a sizable but specific subset of the population rather than the general public at large.
  • Budgetary Magnitude Low Section 2 neither authorizes nor appropriates funds; it creates a coordination mandate only, with funding addressed solely through the separate grant sections.
  • Legal / Regulatory Depth Medium Establishes a new statutory program with a mandatory coordination duty spanning three federal agencies — the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Health Resources and Services Administration (HRSA) — a new cross-agency obligation, but one that governs agency process rather than restructuring substantive law.
  • Degree of Discretion Granted Medium The Secretary of Health and Human Services (HHS) must carry out the program ('shall') with defined goals, but how coordination across CDC, NIH, and HRSA is structured and resourced is left to executive discretion.
  • Implementation & Enforcement Burden Low No enforcement mechanisms or penalties are created; the coordination mandate is an internal executive obligation with no external compliance requirements.
  • Temporal Commitment High The program operates indefinitely with no sunset, expiry, or mandatory reauthorization, persisting until Congress affirmatively acts to end it.
No signal yet

Funding / Appropriations Top 3

Grants for Blood Cancer Diagnostics and Treatment Research

Authorizes grants to universities and academic medical centers to research improved diagnostics, novel treatments, risk factors, and genetic predisposition screening for blood cancer, aiming to expand access to early detection and care.

  • Population Scope Low Grants are restricted to a narrow class of eligible recipients — institutions of higher education and academic medical centers — with downstream benefits accruing only to blood cancer patients over time through eventual research outputs.
  • Budgetary Magnitude Medium No specific dollar amount is authorized or appropriated; the program creates competitive grant authority whose scale is entirely subject to future appropriations.
  • Legal / Regulatory Depth Medium Creates a new statutory grant entitlement class with tightly defined eligibility tied to existing legal definitions under 20 U.S.C. 1001(a) and 42 CFR 411.355(e)(2), imposing a new mandatory duty on Department of Health and Human Services (HHS) without restructuring existing substantive law.
  • Degree of Discretion Granted Medium Eligibility criteria are more tightly constrained by cross-referenced statutory and regulatory definitions than in Section 3, limiting the Secretary of Health and Human Services's discretion over who may receive grants, though award amounts and research priorities remain at the Secretary of Health and Human Services's judgment.
  • Implementation & Enforcement Burden Low No enforcement mechanisms, penalties, or compliance obligations are created; administration relies on existing HHS grant management infrastructure.
  • Temporal Commitment High The grant authority operates indefinitely with no sunset, expiry, or mandatory reauthorization, persisting until Congress affirmatively acts to end it.
No signal yet

No possible riders have been surfaced for this bill.

Summary

This bill creates the National Blood Cancer Program (NBCP) within the Department of Health and Human Services (HHS). The NBCP would coordinate efforts across federal agencies to improve public awareness, train health professionals, and support blood cancer patients and caregivers. It would fund grants for research on education and awareness, as well as grants to universities and medical centers to improve diagnosis and treatment access, with annual reports required to Congress.

AI-generated summary, pending human review.

Full bill text rendering is coming soon.

In the meantime, read the full text on Congress.gov ↗.

Version Event Date User support Your vote Roll calls
Original
Initial publication
Oct 22, 2026
Oct 22, 2026 No votes yet — —

Funding / Appropriations Top 3

Grants for Blood Cancer Awareness and Education

Authorizes grants to state, local, tribal, and nongovernmental health entities to research best practices for blood cancer awareness and education, with priority given to communities with high blood cancer rates or significant mortality.

  • Population Scope Medium Grants flow directly to a bounded set of state, local, tribal, and nongovernmental health entities, but the downstream awareness campaigns they fund could reach a broad general public audience indirectly.
  • Budgetary Magnitude Medium No specific dollar amount is authorized or appropriated; the program creates competitive grant authority whose scale is entirely subject to future appropriations.
  • Legal / Regulatory Depth Medium Creates a new statutory grant entitlement class with defined eligibility criteria and a mandatory priority-setting rule — a new procedural-plus-substantive duty on the Department of Health and Human Services (HHS) Secretary, but not a broad mandate restructuring existing law.
  • Degree of Discretion Granted High The Secretary of Health and Human Services must award grants ('shall') but retains wide latitude to define 'qualified nongovernmental entity,' set award amounts, and determine what constitutes a high-risk community — broad delegated judgment on all substantive criteria.
  • Implementation & Enforcement Burden Low No enforcement mechanisms, penalties, or compliance obligations are created; the only administrative load is grant award and oversight within an existing HHS infrastructure.
  • Temporal Commitment High The grant authority operates indefinitely with no sunset, expiry, or mandatory reauthorization, persisting until Congress affirmatively acts to end it.
No signal yet

Funding / Appropriations

Grants for Blood Cancer Awareness and Education

Core Policy Mechanism Top 3

National Blood Cancer Program Establishment

Creates a new federal program to coordinate blood cancer awareness, health professional education, and patient support across federal agencies including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Health Resources and Services Administration (HRSA).

  • Population Scope Medium The program targets blood cancer patients, caregivers, and health professionals — a sizable but specific subset of the population rather than the general public at large.
  • Budgetary Magnitude Low Section 2 neither authorizes nor appropriates funds; it creates a coordination mandate only, with funding addressed solely through the separate grant sections.
  • Legal / Regulatory Depth Medium Establishes a new statutory program with a mandatory coordination duty spanning three federal agencies — the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Health Resources and Services Administration (HRSA) — a new cross-agency obligation, but one that governs agency process rather than restructuring substantive law.
  • Degree of Discretion Granted Medium The Secretary of Health and Human Services (HHS) must carry out the program ('shall') with defined goals, but how coordination across CDC, NIH, and HRSA is structured and resourced is left to executive discretion.
  • Implementation & Enforcement Burden Low No enforcement mechanisms or penalties are created; the coordination mandate is an internal executive obligation with no external compliance requirements.
  • Temporal Commitment High The program operates indefinitely with no sunset, expiry, or mandatory reauthorization, persisting until Congress affirmatively acts to end it.
No signal yet

Core Policy Mechanism

National Blood Cancer Program Establishment

Funding / Appropriations Top 3

Grants for Blood Cancer Diagnostics and Treatment Research

Authorizes grants to universities and academic medical centers to research improved diagnostics, novel treatments, risk factors, and genetic predisposition screening for blood cancer, aiming to expand access to early detection and care.

  • Population Scope Low Grants are restricted to a narrow class of eligible recipients — institutions of higher education and academic medical centers — with downstream benefits accruing only to blood cancer patients over time through eventual research outputs.
  • Budgetary Magnitude Medium No specific dollar amount is authorized or appropriated; the program creates competitive grant authority whose scale is entirely subject to future appropriations.
  • Legal / Regulatory Depth Medium Creates a new statutory grant entitlement class with tightly defined eligibility tied to existing legal definitions under 20 U.S.C. 1001(a) and 42 CFR 411.355(e)(2), imposing a new mandatory duty on Department of Health and Human Services (HHS) without restructuring existing substantive law.
  • Degree of Discretion Granted Medium Eligibility criteria are more tightly constrained by cross-referenced statutory and regulatory definitions than in Section 3, limiting the Secretary of Health and Human Services's discretion over who may receive grants, though award amounts and research priorities remain at the Secretary of Health and Human Services's judgment.
  • Implementation & Enforcement Burden Low No enforcement mechanisms, penalties, or compliance obligations are created; administration relies on existing HHS grant management infrastructure.
  • Temporal Commitment High The grant authority operates indefinitely with no sunset, expiry, or mandatory reauthorization, persisting until Congress affirmatively acts to end it.
No signal yet

Funding / Appropriations

Grants for Blood Cancer Diagnostics and Treatment Research